Lipopeptides

Cubist announced on its January 2008 Earnings Call that it is setting aside work on lipopeptide drug candidates for lung infections. Desirable candidates would have CUBICIN-like efficacy and safety as well as potency in the presence of lung surfactant. Cubist scientists have progressed a number of candidates, but further work would be required to meet the company's target therapeutic index. Cubist discovery and development resources in 2008 are focused on other programs with near term IND potential.